| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-12-30 | BGB-A317 | advanced solid tumors | 1 | BeiGene (China) | Cancer - Oncology |
| 2016-12-30 | ruxolitinib | graft-versus-host disease | 2 | Incyte (USA - DE) | Transplantation |
| 2016-12-29 | Resunab™- JBT-101 - (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-Dibenzo(b,d)pyran-9-carboxylic acid | cystic fibrosis | 2 | Corbus Pharmaceuticals (USA - MA) | Rare diseases - Genetic diseases |
| 2016-12-29 | CV301 in combination with Opdivo® (nivolumab) | non-small cell lung cancer (NSCLC) | 1-2 | Bavarian Nordic (Denmark) | Cancer - Oncology |
| 2016-12-29 | ARGX-110 | acute myeloid leukemia (AML) | preclinical | Argen-X (Belgium - The Netherlands) | Cancer - Oncology |
| 2016-12-29 | PH-10 | psoriasis | 2 | Provectus Pharmaceuticals (USA - TN) | Autoimmune diseases - Dermatological diseases |
| 2016-12-29 | PV-10 | melanoma | 1 | Provectus Pharmaceuticals (USA - TN) | Cancer - Oncology |
| 2016-12-28 | GALE-401 (anagrelide controlled release ) | essential thrombocythemia | 3 | Galena Biopharma (USA - OR) | |
| 2016-12-27 | Sollpura® (liprotamase) | cystic fibrosis patients with exocrine pancreatic insufficiency | 3 | Anthera Pharmaceuticals (USA - CA) | Rare diseases - Genetic diseases |
| 2016-12-27 | sacituzumab govitecan (IMMU-132) | triple-negative breast cancer | 2 | Immunomedics (USA - NJ) | Cancer - Oncology |
| 2016-12-27 | MYL-1401O - biosimilar version of trastuzumab | breast cancer | 3 | Mylan (USA - PA) Biocon (India) | Cancer - Oncology |
| 2016-12-26 | MGD011 (JNJ-64052781) | relapsed or refractory B-cell malignancies, including diffuse-large B cell lymphoma, follicular lymphoma, mantle-cell lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia | 1 | Janssen Biotech, a J&J company (USA - NJ) | Cancer - Oncology |
| 2016-12-23 | Aravive-S6 | preclinical | Aravive Biologics (USA - TX) | Cancer - Oncology | |
| 2016-12-23 | choroideremia | observational | 4D Molecular Therapeutics (USA - CA) | Rare diseases - Genetic diseases - Ophtalmological diseases | |
| 2016-12-23 | Jetrea® (ocriplasmin) | posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR) | 2 | Thrombogenics (Belgium) | Ophtalmological diseases |
| 2016-12-22 | ND0612H (levodopa and carbidopa administered through a pump patch) | Parkinson's disease | 2 | Neuroderm (Israel) | Neurodegenerative diseases |
| 2016-12-22 | BHV-4157 | spinocerebellar ataxias | 2-3 | Biohaven Pharmaceuticals (USA - CT) | Rare diseases - Neurodegenerative diseases - Neurological diseases |
| 2016-12-22 | linaclotide colonic release-2 (CR2) formulation | irritable bowel syndrome with constipation (IBS-C) | 2b | Ironwood Pharmaceuticals (USA - MA) Allergan (Ireland) | Inflammatory diseases - Gastrointestinal diseases |
| 2016-12-21 | Soliris® (eculizumab) | delayed graft function | 2-3 | Alexion Pharmaceuticals (USA - CT) | Cancer - Oncology |
| 2016-12-21 | CTP-656 (D9-ivacaftor ) deuterated ivacaftor | cystic fibrosis | 2 | Concert Pharmaceuticals (USA - MA) | Rare diseases - Genetic diseases |
